TriaGen Wealth Management LLC Has $358,000 Position in Axon Enterprise, Inc $AXON

Key Points

• TriaGen Wealth Management LLC reduced its stake in Axon Enterprise, Inc by 88.5% during Q2, now holding shares worth $358,000.
• Axon Enterprise reported earnings of $2.12 per share for the last quarter, surpassing analyst expectations, with revenues of $668.54 million, up 32.6% year-over-year.
• Analysts have a consensus rating of "Moderate Buy" for Axon, with a target price averaging $841.64, reflecting positive sentiment despite insider stock sales.

TriaGen Wealth Management LLC lessened its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 88.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 433 shares of the biotechnology company's stock after selling 3,321 shares during the quarter. TriaGen Wealth Management LLC's holdings in Axon Enterprise were worth $358,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AXON. TCTC Holdings LLC raised its position in Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 24 shares in the last quarter. Bartlett & CO. Wealth Management LLC boosted its holdings in Axon Enterprise by 132.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 33 shares in the last quarter. Catalyst Capital Advisors LLC bought a new stake in shares of Axon Enterprise in the 1st quarter valued at approximately $32,000. Banque Transatlantique SA acquired a new position in shares of Axon Enterprise in the 1st quarter worth approximately $31,000. Finally, Flaharty Asset Management LLC acquired a new position in shares of Axon Enterprise in the 1st quarter worth approximately $33,000. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $721.59 on Tuesday. The business has a fifty day moving average of $757.50 and a 200-day moving average of $710.51. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a twelve month low of $416.88 and a twelve month high of $885.91. The firm has a market cap of $56.65 billion, a PE ratio of 178.17, a price-to-earnings-growth ratio of 27.79 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $668.54 million during the quarter, compared to analysts' expectations of $641.77 million. During the same quarter last year, the company posted $1.20 EPS. The company's quarterly revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, President Joshua Isner sold 15,919 shares of the business's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the completion of the sale, the president owned 238,379 shares in the company, valued at $177,892,712.54. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Jennifer H. Mak sold 77 shares of the company's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $760.00, for a total value of $58,520.00. Following the transaction, the chief accounting officer directly owned 15,003 shares in the company, valued at $11,402,280. This trade represents a 0.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 49,932 shares of company stock valued at $37,978,216 over the last quarter. Company insiders own 4.40% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on AXON shares. Morgan Stanley set a $885.00 price target on Axon Enterprise and gave the company an "overweight" rating in a research note on Friday, July 11th. Northland Securities set a $800.00 price objective on Axon Enterprise in a report on Tuesday, August 5th. UBS Group reaffirmed a "neutral" rating and issued a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Piper Sandler started coverage on shares of Axon Enterprise in a research report on Tuesday, September 23rd. They set an "overweight" rating and a $893.00 target price for the company. Finally, JMP Securities restated a "market outperform" rating and issued a $825.00 price target on shares of Axon Enterprise in a research report on Monday, September 29th. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.